Xenetic Biosciences Enters Into Definitive Share Exchange Agreement to Acquire Santersus AG

Filing content

Xenetic Biosciences has entered into a definitive agreement to acquire all outstanding shares of Santersus AG in an all-stock transaction, with existing Xenetic shareholders expected to hold approximately 15% of the combined company.